Scioderm
Scioderm is a privately held, clinical-stage pharmaceutical company founded in 2012 and based in Durham, North Carolina that develops topical pharmaceutical products for the treatment of chronic skin diseases.
- Company typePrivate
- Founded2002
- HeadquartersDurham, United States
- Headcount11–50
- GTM typeB2B
- OfferingHardware or Manufacturing
What Scioderm does
Scioderm is a privately held, clinical-stage pharmaceutical company founded in 2012 and headquartered in Durham, North Carolina. The company develops topical pharmaceutical products intended for the treatment of chronic skin diseases, positioning itself within the dermatology drug development segment of the specialty pharmaceutical industry. As a clinical-stage entity with no commercial products indicated in the source material, Scioderm's operations are organized around advancing topical therapeutic candidates through regulatory and clinical milestones. The company operates with a focused headcount of 11-50 employees and has maintained a single-site footprint in Durham, NC.
Scioderm firmographics
Firmographics- Name
- Scioderm
- Legal name
- Amicus Therapeutics, Inc.
- Website
- https://sderm.com
- Company type
- Private
- Founded year
- 2002
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- Scioderm is a privately held, clinical-stage pharmaceutical company founded in 2012 and based in Durham, North Carolina that develops topical pharmaceutical products for the treatment of chronic skin diseases.
- Ownership category
- akta.pro rank
Scioderm industry classification
Industry- Product category
- Topical Dermatological Pharmaceuticals
- NAICS
- Biological Product (except Diagnostic) Manufacturing (325414)
- SIC
- Services-Commercial Physical & Biological Research (8731)
- akta.pro primary industry
- Dermatology & Aesthetics Pharmaceuticals (HLAIAAAK)
- akta.pro secondary industries
- Dermatology Specialty Pharmaceuticals (HLAIACAL), Dermatology & Topical Skin Treatments (HLAIADAE)
Keywords
Where Scioderm is headquartered
LocationHeadquarters
- HQ city
- Durham
- HQ country
- United States
- HQ region
- North America
Markets served
Scioderm business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Personnel, Operations
Distribution channels1 record
Marketing channels2 records
Scioderm product offering
Product offeringCore offering
Scioderm is a clinical-stage pharmaceutical company that develops topical products for the treatment of chronic skin diseases. Founded in 2012 and headquartered in Durham, United States, the company focuses on the research and development of topical therapies targeting chronic dermatological conditions.
Differentiator
Problem solved
Functional benefit
Companies that use Scioderm
Customer profileSegments1 record
Ideal customer profiles1 record
Scioderm technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Scioderm partnerships and signals
Strategic signalPartnerships
One partnership is on record.
- BioMarin Pharmaceutical Inc.flagshipBioMarin Pharmaceutical Inc. is the parent company and sole owner of Amicus Therapeutics. Amicus operates as a wholly owned subsidiary of BioMarin, which is described as a leading global rare disease biotechnology company focused on delivering medicines for people living with genetically defined conditions.
Recent moves4 records
Expansion highlights3 records
Scioderm competitors and assessment
Company assessmentDirect peers
- Amicus Therapeutics: Amicus Therapeutics acquired Scioderm in 2015 and operates as a wholly owned subsidiary of BioMarin focused on rare disease therapeutics, including dermatology assets developed by Scioderm. Directly comparable as the parent platform for Scioderm's pipeline and commercial infrastructure.
- Dermavant Sciences: Dermavant develops topical therapeutics for skin diseases including psoriasis and atopic dermatitis. Comparable in modality (topical) and chronic dermatology focus.
- Novan: Novan developed topical nitric oxide-based therapies for skin diseases such as atopic dermatitis. Comparable in modality (topical) and indication focus on chronic inflammatory skin diseases.
- Arcutis Biotherapeutics: Arcutis is a clinical-to-commercial medical dermatology company developing topical treatments for chronic skin diseases. Closely comparable in therapeutic area (chronic dermatology), modality (topicals), and target indications.
- Verrica Pharmaceuticals: Verrica is a dermatology-focused clinical-stage pharma company developing topical therapies for skin diseases, including rare conditions. Comparable as a small-cap clinical-stage player in topical dermatology.
- Aclaris Therapeutics: Aclaris is a clinical-stage dermatology company developing immunomodulatory and topical therapies for inflammatory skin diseases. Comparable in therapeutic area and clinical-stage profile.
Broad incumbents
- BioMarin Pharmaceutical: BioMarin is the parent company of Scioderm (via Amicus) and a leading global rare disease biotech with a broad pipeline. Comparable as the strategic owner that funds, develops, and commercializes rare disease therapies including Scioderm's dermatology programs.
- Galderma: Galderma is one of the largest pure-play dermatology companies globally, with a broad portfolio across therapeutic and aesthetic skin conditions. Comparable as a broad incumbent in dermatology, though larger and more diversified than Scioderm.
Emerging players
- Castle Creek Biosciences: Castle Creek Biosciences is a clinical-stage company developing therapies for rare dermatologic and connective tissue diseases. Comparable as a small clinical-stage player in rare/serious skin diseases.
- Anacor Pharmaceuticals: Anacor was a clinical-stage topical dermatology company (acquired by Pfizer in 2016) developing boron-based topical therapeutics for skin conditions. Comparable as a topical dermatology specialty biotech at a similar stage of maturity.
Market position
Strengths4 records
Weaknesses4 records
Competitive moat3 records
Key risks5 records
Key highlights5 records
Customer concentration
Scioderm social profiles
Digital presenceScioderm financial estimates
Financial estimateRevenue estimate
Valuation estimate
Scioderm leadership team
Management profileNumber of profiles
Scioderm funding detail
Funding detailFunding overview
Funding rounds3 records
Investors3 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Scioderm M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Scioderm
What does Scioderm do?
Scioderm is a clinical-stage pharmaceutical company that develops topical products for the treatment of chronic skin diseases. Founded in 2012 and headquartered in Durham, United States, the company focuses on the research and development of topical therapies targeting chronic dermatological conditions.
Is Scioderm a public or private company?
Scioderm is a private company. It is classified as venture growth investor backed and is currently operating.
When was Scioderm founded?
Scioderm was founded in 2002. It employs 11 to 50 people.
Where is Scioderm based?
Scioderm is headquartered in Durham, United States, in the North America region.
Who are Scioderm's main competitors?
Direct peers on record are Amicus Therapeutics, Dermavant Sciences, Novan, Arcutis Biotherapeutics, Verrica Pharmaceuticals and Aclaris Therapeutics. Broad incumbents are BioMarin Pharmaceutical and Galderma. Emerging players are Castle Creek Biosciences and Anacor Pharmaceuticals.
Does Scioderm have an API?
No public API is recorded for Scioderm.
What industry is Scioderm in?
Scioderm's product category is Topical Dermatological Pharmaceuticals. Its primary akta.pro industry code is HLAIAAAK, Dermatology & Aesthetics Pharmaceuticals, with a secondary code of HLAIACAL, Dermatology Specialty Pharmaceuticals. Its NAICS code is 325414 and its SIC code is 8731.